Tectonic Therapeutic Inc (NASDAQ: TECT) is a biotechnology company developing novel GPCR-targeted therapies for rare and chronic diseases. Using structure-based drug design and proprietary platform technology, it aims to unlock previously undruggable receptors. Tectonic’s shares move with clinical milestones, licensing partnerships, and progress advancing its pipeline of precision therapeutics.